Form 8-K Humacyte, Inc. For: Mar 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Humacyte suspends $60 million stock offering program
March 19, 2026 8:28 AM EDTHumacyte Inc. (NASDAQ: HUMA) terminated its at-the-market equity offering program on March 19, 2026, according to a company statement.
The biotechnology company delivered written notice to TD Securities (USA) LLC, which served as the sales agent, suspending the prospectus dated December 16, 2025. The prospectus... More
